Journals / Diagnostic and Interventional Radiology / 2018 / Cilt: 24 - Sayı: 4

Dynamic contrast-enhanced MRI for advanced esophageal cancer response assessment after concurrent chemoradiotherapy

Pages
195–202
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Based on ROC analysis, the ratio of change in Ktrans was the best parameter to assess treatment response (AUC= 0.840).CONCLUSIONDCE-MRI parameters are valuable in predicting and assessing concurrent CRT response for advanced esophageal cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSEWe aimed to evaluate the treatment response of patients with esophageal cancer after concurrent chemoradiation therapy (CRT) using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).METHODSThis retrospective study included 59 patients with histologically confirmed esophageal squamous cell carcinoma.
📊
Key Findings & Data:The patients underwent DCE-MRI before and 4 weeks after CRT.
💡
Conclusion & Impact:Based on ROC analysis, the ratio of change in Ktrans was the best parameter to assess treatment response (AUC= 0.840).CONCLUSIONDCE-MRI parameters are valuable in predicting and assessing concurrent CRT response for advanced esophageal cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

PURPOSEWe aimed to evaluate the treatment response of patients with esophageal cancer after concurrent chemoradiation therapy (CRT) using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).METHODSThis retrospective study included 59 patients with histologically confirmed esophageal squamous cell carcinoma. The patients underwent DCE-MRI before and 4 weeks after CRT. Patients with complete response were defined as the CR group; partial response, stable disease, and progressive disease patients were defined as the non-CR group. DCE-MRI parameters (Ktrans, Ve, and Kep) were measured and compared between pre- and post-CRT in the CR and non-CR groups, respectively. Pre-CRT and post-CRT parameters were used to calculate the absolute change and the ratio of change. DCE-MRI parameters were compared between the CR and non-CR groups. Receiver operating characteristic (ROC) curves were used to verify diagnostic performance.RESULTSPatients with higher T-stage esophageal cancer might present with poorer response. After CRT, the Ktrans and Kep values significantly decreased in the CR group, whereas only Kep value decreased in the non-CR group. The post-Ktrans and post-Kep values were observed to be significantly lower in the CR group than in the non-CR group. The absolute change and ratio of change of both Ktrans and Kep were higher in the CR group than in the non-CR group. Based on ROC analysis, the ratio of change in Ktrans was the best parameter to assess treatment response (AUC= 0.840).CONCLUSIONDCE-MRI parameters are valuable in predicting and assessing concurrent CRT response for advanced esophageal cancer.

🔖

Cite This Article

SUN, N., LİU, C., GE, X., WANG, J. (2018). Dynamic contrast-enhanced MRI for advanced esophageal cancer response assessment after concurrent chemoradiotherapy. Diagnostic and Interventional Radiology, Cilt: 24 - Sayı: 4, 195–202. https://ajindex.com/articles/350031

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010
  2. 2893–2917. [CrossRef] 2. Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet 2013
  3. 400–412. [CrossRef] 3. Liu S, Zhen FX, Sun NN, et al. Apparent diffusion coefficient values detected by diffusion-weighted imaging in the prognosis of patients with locally advanced esophageal squamous cell carcinoma receiving chemoradiation. Onco Targets Ther 2016
  4. 5791–5796. [CrossRef] 4. Heethuis SE, Rossum PSN, Lips IM, et al. Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy. Radiother Oncol 2016
  5. 128–135. [CrossRef] 5. Rossum PSN, Lier ALHMW, Vulpen M, et al. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer. Radiother Oncol 2015
  6. 163–170. [CrossRef] 6. Imanishi S, Shuto K, Aoyagi T, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma. Dig Surg 2013
  7. 240–248. [CrossRef] 7. Wang CH, Yin FF, Horton J, et al. Review of treatment assessment using DCE-MRI in breast cancer radiation therapy. World J Methodol 2014
  8. 46–58. [CrossRef] 8. Huang W, Beckett BR, Tudorica A, et al. Evaluation of soft tissue sarcoma response to preoperative chemoradiotherapy using dynamic contrast-enhanced magnetic resonance imaging. Tomography 2016
  9. 308–316. [CrossRef] 9. Kim JH, Kim CK, Park BK, et al. Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy. Eur Radiol 2012
  10. 2533–2599. [CrossRef] 10. Chikui T, Kitamoto E, Kawano S, et al. Pharmacokinetic analysis based on dynamic contrast-enhanced MRI for evaluating tumor response to preoperative therapy for oral cancer. J Magn Reson Imaging 2012
  11. 589–597. [CrossRef] 11. Xu XQ, Choi YJ, Sung YS, et al. Intravoxel incoherent motion MR imaging in the head and neck: correlation with dynamic contrast-enhanced MR imaging and diffusion-weighted imaging. Korean J Radiol 2016
  12. 641–649. [CrossRef] 12. Tong T, Sun YQ, Gollub MJ, et al. Dynamic contrast-enhanced MRI: use in predicting pathological complete response to neoadjuvant chemoradiation in locally advanced rectal cancer. J Magn Reson Imaging 2015
  13. 673–680. [CrossRef] 13. Lerant G, Sarkoz